Dr. Vivek Subbiah is an Associate Professor in the Investigational Cancer Therapeutics department at the University of Texas MD Anderson Cancer Center. He is the Clinical Medical Director of the Clinical Center for Targeted Therapy.

Dr. Subbiah is board certified in Internal Medicine and Paediatrics and has completed fellowships in both adult and paediatric oncology at MD Anderson.

Dr. Subbiah is a Clinical Trialist and Physician Investigator in the Department of Investigational Cancer Therapeutics at MD Anderson, which is the largest oncology drug development unit in the world. He is primarily involved in translational cancer research and the design and conduct of early-phase biomarker-driven clinical trials, with special interest in anti-body drug conjugates, radiopharmaceuticals, immunoconjugates and basket trials. Dr. Subbiah serves as the Principal Investigator in numerous trials, leaving an accomplished impression on the national and international drug development community.

Dr. Subbiah is a major advocate for precision oncology. His national leadership roles continue to expand as the National Principal Investigator or the BRAF non-V600 alteration arm of the NCI-MATCH Precision Medicine Clinical Trial. His trial portfolio includes trials that target BRAF, MEK, RET, CDK, WNT, VEGF, mTOR, EZH2-EED pathways, novel immunotherapy combination trials GITR, TLR7/9, PD1, WT1, several first-in-human antibody drug conjugates, oncolytic viruses, intra-tumoral therapies and radiopharmaceuticals.

He has published over 150 peer-reviewed in several prestigious journals such as the New England Journal of Medicine, Journal of Clinical Oncology, JAMA Oncology, Cancer Discovery, Clinical Cancer Research, and Lancet Oncology.